[Insulin receptors in intrauterine growth retardation]

J Jordán1, M C Blasco, M G Juste

  • 1Departamento de Pediatría y Puericultura, Facultad de Medicina, Hospital Clínico Universitario de Zaragoza.

Insights

Neonatal small for gestational age infants show increased insulin sensitivity due to altered erythrocyte insulin receptors. This suggests a compensatory mechanism in response to chronic undernutrition.

Area of Science:

  • Endocrinology
  • Neonatal Physiology
  • Metabolic Research

Context:

  • Neonatal period is critical for metabolic development.
  • Intrauterine growth restriction (IUGR) impacts infant physiology.
  • Erythrocyte insulin receptors play a role in glucose homeostasis.

Purpose:

  • To analyze erythrocyte insulin binding and receptors in newborns.
  • To compare insulin sensitivity in term infants versus small for gestational age (SGA) infants.
  • To investigate the relationship between birth weight and insulin receptor characteristics in SGA infants.

Summary:

  • Studied 30 normal and 15 SGA newborns, measuring cord blood insulin binding, receptors, glucose, insulin, C-peptide, and C-peptide/insulin ratio.
  • SGA infants exhibited significantly lower affinity and higher dissociation constants for erythrocyte insulin receptors (p=0.05).
  • A negative correlation was found between the number of insulin receptor sites per cell and birth weight in SGA infants (r=-0.57, p<0.05).

Impact:

  • Findings suggest increased insulin sensitivity in SGA infants, potentially due to receptor upregulation as a response to chronic undernutrition.
  • Provides insights into the mechanisms of insulin resistance and adaptation in growth-restricted neonates.
  • Highlights the importance of erythrocyte insulin receptor analysis for understanding neonatal metabolic adaptation.

Related Concept Videos

Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...